Heart Failure with preserved Ejection Fraction (HFpEF) with or without concomitant Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Conditions
Brief summary
Change in VO2max (ml/kg/min) during 4 hours of continuous subcutaneous administration of glucagon at a dose of 8 ng/kg/min.
Detailed description
Change in energy expenditure (kcal/min) or substrate utilisation (respiratory exchange ratio) during a 4-hour continuous subcutaneous infusion of glucagon at a dose of 8 ng/kg/min, Plasma bioavailability of glucagon (area under the curve, Cmax, Tmax) and change in plasma ketone body concentration (Cmax) during a 4-hourly continuous subcutaneous infusion of glucagon at a dose of 8 ng/kg/min.
Interventions
DRUGHuman-Albumin 20 % Behring
DRUGsalzarm Infusionslösung
DRUGGlucaGen 1 mg
DRUGPulver und Lösungsmittel zur Herstellung einer Injektionslösung
DRUGGlucaGen HypoKit 1mg
Sponsors
Katholisches Klinikum Bochum gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in VO2max (ml/kg/min) during 4 hours of continuous subcutaneous administration of glucagon at a dose of 8 ng/kg/min. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in energy expenditure (kcal/min) or substrate utilisation (respiratory exchange ratio) during a 4-hour continuous subcutaneous infusion of glucagon at a dose of 8 ng/kg/min, Plasma bioavailability of glucagon (area under the curve, Cmax, Tmax) and change in plasma ketone body concentration (Cmax) during a 4-hourly continuous subcutaneous infusion of glucagon at a dose of 8 ng/kg/min. | — |
Countries
Germany
Outcome results
None listed